In our NEW @NEJM publication we found that 1) #Mpox antibody responses after #JYNNEOS vaccination are similar in people with & without #HIV. 2) Antibody #halflife after vaccination was 107 days. 3) No differences in route of 💉 administration!
https://t.co/ZGdmY3kzWS
The federal HIV guidelines are facing a shutdown.
A trusted, living resource — used by clinicians, programs, and public health agencies for decades — may disappear due to “budget decreases and revised priorities.”
Big mistake.
https://t.co/AXmpdBjXNJ
The Trump administration is killing almost all NIH-funded HIV vaccine research:
https://t.co/o3MYzs2yLp
"This is a setback of probably a decade for HIV vaccine research."
Many will needlessly get sick & die because of profound cruelty & vindictiveness.
by me & @Alexander_Tin
The Trump Administration’s Foreign Aid Review: Status of @PEPFAR https://t.co/T9tUGnN5JN HIV testing had been disrupted in 10 countries; there was a risk of ARV stocks outs in 8 & viral load testing stockouts in 13 countries. Oral PrEP medication stock-outs in in 4 countries.
Thanks to Gavi, the Vaccine Alliance, more than 1 billion children have been immunized against the world’s deadliest diseases, like tuberculosis and malaria. Now the U.S. government is reportedly planning to end its support for Gavi—support that’s been critical to this progress for nearly 25 years.
It breaks my heart to think that more than a million children in low-income countries could die over the next five years because of this decision.
It’s no exaggeration to say that the world’s success in immunizing children is one of the greatest achievements in history. It’s also one of the hardest-won. Mothers around the world line up for hours in the heat to get vaccines for their children, women travel through mountains on foot to administer them, and thousands of scientists dedicate their lives to developing them—all because there’s nothing more important than saving the life of a child.
Leaders must reconsider the plan to end support for Gavi. Unraveling one of the most effective systems in global health would be an absolutely devastating choice.
AIDS DEATHS: At #CROI2025- Amazing plenary by Dr. Chris Beyrer. The immediate impacts of stopping PEPFAR are below- surge in AIDS deaths and AIDS orphans starting now. @SecRubio@LindseyGrahamSC@GWBLibrary please help
The removal of #HIV- and #LGBTQ-related resources from the websites of the @CDCgov and other health agencies is deeply concerning.
Access to this information is crucial for ID and HIV health care professionals.
Our full statement: https://t.co/xcqdZ6515p
WHO expresses deep concern about the implications of the immediate funding pause for #HIV programmes in low- and middle-income countries.
These programmes provide access to life-saving HIV therapy to more than 30 million people worldwide.
A funding halt for HIV programmes can put people living with HIV at immediate increased risk of illness and death and undermine efforts to prevent transmission in communities and countries.
Such measures, if prolonged, could lead to rises in new infections and deaths, reversing decades of progress and potentially taking the world back to the 1980s and 1990s when millions died of HIV every year globally, including many in the United States of America.
For the global community, this could result in significant setbacks to progress in partnerships and investments in scientific advances that have been the cornerstone of good public health programming, including innovative diagnostics, affordable medicines, and community delivery models of HIV care.
We call on the Government of the United States of America to enable additional exemptions to ensure the delivery of lifesaving HIV treatment and care.
Read more https://t.co/UWDbvmGGZF
The immediate halting of funding to #PEPFAR places millions of lives in jeopardy. The IAS urgently calls on policy makers and stakeholders to restore the funding lifeline to this pivotal programme.
Lives depend on it, right now.
Read our full statement: https://t.co/dXDQTG5wwt
🔥🔥 NEW 🔥🔥
Year In Review: Top Infectious Diseases Articles From 2024
Our new post, a great collaboration with my friend
🌟 @IDstewardship
1️⃣6️⃣⚡️🆔 RCTs
@JAMA_current@TheLancet ✨
7️⃣Syst Reviews/Meta
3️⃣🌏Guidelines
@Wiki_Guidelines ✨️
#idxposts
https://t.co/8YWtXqoyrx
This was yesterday @IDWeekmtg, one of the most important presentations I've given so far! I am proud of the work that we have done at @nyulangone, I am grateful for such wonderful mentorship from @mjmull, and for my colleagues who are incredibly supporting friends 💜💜💜
At IDWeek 2024 in LA, NYU Vaccine Center Associate Director, Dr Angelica Cifuentes Kottkamp, shared latest results from mpox vaccine study during her Best Abstract Presentation in the Smadel Lecture Plenary session. @NYUGSOM_ID @IDCRC_LG @HelpEndHIV
Blown away by the brilliance of my colleague @angelickott who gave the IDSA Featured Oral Abstract Joseph Smadell Lecture today @IDWeekmtg on humoral responses to mpox. A huge accomplishment! So impressed with you and the entire team @NYUGSOM_ID Vaccine Center!!! #IDTwitter
If all girls complete secondary education by 2030, the GDP for African countries and other developing countries, will increase by 10% over the next ten years.
On today's International #DayoftheGirl, sharing my remarks from the @_AfricanUnion@GPforEducation@Humancapafrica High-level event commemorating the African Union Year of Education 2024 #UNGA79
https://t.co/FNzcAOCqjN
"Remember this product is for who? This is not a Gucci handbag for rich people. This is a product for people who live on the margins.”
- @UNAIDS Executive Director @Winnie_Byanyima 🇺🇳 at #AIDS2024 media roundtable on long-acting injectables, #PutPeopleFirst
Correspondence: Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis https://t.co/kde31menEa
#AIDS2024 | @iasociety
En las opciones del Co-chair en #AIDS2024 inicia con el nuevo paciente Berlin. Un hombre nacido en 1964 que adquiere VIH en 2009. Inicia TAR en 2015 y se diagnostica LMA. Trasp autologo fr células madre hem heterocigoto a mut delta32 CCR5 + 1/